|Articles|January 1, 2003

Management beyond corticosteriods starts with assessing risk to skin, reducing sun exposure

Paris - Treatment for dermatomyositis (DM) begins with sun avoidance and sun-protective measures, Jeffrey P. Callen, M.D., said at the World Congress of Dermatology. "The first line of therapy is to recognize that the patient is photosensitive."

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe

Related Content

Why Dermatologists Are on the Front Lines of Youth Body Dysmorphic Disorder

ByMarie Bosslett, Assistant Editor

July 25th 2026

Nanette Silverberg, MD, on Managing Comorbidities and Quality of Life in Pediatric Vitiligo

ByNanette Silverberg, MD,Marie Bosslett, Assistant Editor

July 25th 2026

Tapinarof Cream Shows Consistent Response Across Pediatric AD Age Groups

ByLinda Stein Gold, MD,Kaitlyn Bader, Assistant Managing Editor

July 24th 2026

Mark Koh, MD, on Pathology, Genetics, and Global Collaboration in Pediatric Dermatology

ByMark Koh, MD,Marie Bosslett, Assistant Editor

July 24th 2026

Q&A: Amy S. Paller, MD, MS, Reflects on Receiving the Prestigious Alvin H. Jacobs Award

ByMarie Bosslett, Assistant Editor,Amy S. Paller, MS, MD

July 24th 2026

Latest CME

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Management beyond corticosteriods starts with assessing risk to skin, reducing sun exposure

Related Content

Why Dermatologists Are on the Front Lines of Youth Body Dysmorphic Disorder

Nanette Silverberg, MD, on Managing Comorbidities and Quality of Life in Pediatric Vitiligo

Tapinarof Cream Shows Consistent Response Across Pediatric AD Age Groups

Mark Koh, MD, on Pathology, Genetics, and Global Collaboration in Pediatric Dermatology

Q&A: Amy S. Paller, MD, MS, Reflects on Receiving the Prestigious Alvin H. Jacobs Award

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Trending on Dermatology Times

Sanofi Discontinues Development of OX40L Inhibitor Amlitelimab in Atopic Dermatitis

Why Dermatologists Are on the Front Lines of Youth Body Dysmorphic Disorder

Tapinarof Cream Shows Consistent Response Across Pediatric AD Age Groups

Sunscreen’s New Blind Spot: Fashion Trends, Tanning Myths, and the Rise of Gluteal Melanomas

Nanette Silverberg, MD, on Managing Comorbidities and Quality of Life in Pediatric Vitiligo